SHANGHAI & SUZHOU, China & GERMANTOWN, Md.–(BUSINESS WIRE)–Elpiscience Biopharmaceuticals, Inc. (�Elpiscience), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase conference during J.P. Morgan Week 2023 in San Francisco in January. Elpisciences Co-Founder and CEO Darren Ji will also be sharing his perspective on the BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities panel at the conference.
We are excited to bring to the world our novel immunotherapies, including our first-in-class anti-CD39/TGF-? bispecific antibody ES014 potentially for PD-(L)1 resistant patient population, a highly differentiated anti-LILRB2 antibody ES009, and a pan-acting anti-SIPR? antibody ES004. We look forward to collaborating with pharmaceutical partners to advance our innovative drug candidates to benefit cancer patients worldwide, said Darren Ji, Co-Founder, and CEO of Elpiscience.
Event Schedules:
Elpisciences presentation
Darren Ji, Co-Founder and CEO of Elpiscience
Date and Time: 9 January 2023, 14:30 14:45 PST
Location: Hilton Union Square, Franciscan C (Ballroom Level), San Francisco CA
Panel: BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities
Darren Ji, Co-Founder and CEO of Elpiscience
Date and Time: 10 January 2023, 9:00 10:00 PST
Location: Hilton Union Square, Imperial Ballroom, San Francisco CA
Elpisciences team is participating in partnering system and welcomes the opportunity to meet with potential partners. For meeting appointments, registered attendees can send a request through Biotech Showcase Partnering Platform, and or by contacting Elpiscience directly at BD@elpiscience.com.
About Elpiscience
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide. The Company has a robust pipeline of globally innovative cancer immunotherapies covering a wide range of oncology targets and multiple proprietary technologies to enable discovery including its Bispecific Macrophage Engager (BiME®) antibody platform for solid tumors, human antibody Fab library ElpiSource and H-L interchain disulfide bond engineering BsAb platform Acebody.
Founded and managed by a team of biotechnology industry leaders and scientists, Elpiscience is supported by a world-class Scientific Advisory Board and high-quality investors including Lilly Asia Ventures, GL Ventures, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.
For more information, please visit www.elpiscience.com.
Contacts
BD inquiries:
BD@elpiscience.com
Investor inquiries:
IR@elpiscience.com
Media inquiries:
PR@elpiscience.com
SINGAPORE - Media OutReach Newswire - 29 April 2024 - XT, the world's first socially…
LONDON--(BUSINESS WIRE)--#BonteFriedheim--NextEnergy Capital (“NEC”), a leading global renewables manager specialised on the solar+ infrastructure sector,…
H2SITE’s AMMONIA to H2POWER technology for ammonia cracking on-board has received Approval in Principle (AiP)…
Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients…
Q1 2024 Group sales at $7.4 billion, -20% (-18% at CER) versus prior year Q1…
Hongkong Land sees success in its unique and fully owned tenant-based, community initiative that promotes…
